Posted by Michael Wonder on 18 Jun 2023
Health economic assessment of Carvykti in the treatment of multiple myeloma
16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel).
The assessment concerns the treatment of adults with relapsed and refractory multiple myeloma who have received at least three previous treatments, including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody, and who have shown worsening of the disease on the last treatment.
